Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic Cancers

NCT02367196 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02367196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02367196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic Cancers
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
March 12, 2015
Completion date
December 24, 2020
Enrollment
60 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic neoplasms